Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:41:45.284Z.
Consensus retrieved: 2026-10-06T11:11:11.075Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:41:45.284Z.
Quote observation: 2026-10-06T15:40:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc19b8de49e3e4106715fdbdfbea2d0d88a0c8d359e91a5f261ed42d8782af4c
Forward PE Ratio (N/A) = Dated Quote Price ($1.47) / Consensus Forward EPS ($-315.00)
FORWARD PE RATIO
N/A
Enveric Biosciences, Inc.
Market Cap
$6.58M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | $6.58M | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.63M | N/A |
| Aclarion, Inc. (ACON)vs › | $6.69M | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.42M | N/A |
| Femasys Inc. (FEMY)vs › | $6.31M | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.21M | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.02M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.08M | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.01M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.47, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-315.00 | $-315.00 – $-315.00 | 1 | n/m |
| 2027-12-31 | $-111.60 | $-111.60 – $-111.60 | 1 | n/m |
| 2028-12-31 | $-43.20 | $-43.20 – $-43.20 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
